277 related articles for article (PubMed ID: 16670082)
1. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
2. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
3. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
5. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
6. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
7. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
8. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS).
Boissinot M; Garand R; Hamidou M; Hermouet S
Blood; 2006 Sep; 108(5):1781-2. PubMed ID: 16926301
[No Abstract] [Full Text] [Related]
9. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults.
Shaw GR
Br J Haematol; 2005 Oct; 131(2):180-4. PubMed ID: 16197447
[TBL] [Abstract][Full Text] [Related]
10. [Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies].
Gérard J; Dubois-Galopin F; Gardembas-Pain M; Defaux JB; Schmidt-Tanguy A; Godon A; Geneviève F; Blanchet O; Ifrah N; Zandecki M
Ann Biol Clin (Paris); 2005; 63(6):653-9. PubMed ID: 16330386
[TBL] [Abstract][Full Text] [Related]
11. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
[No Abstract] [Full Text] [Related]
12. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
[TBL] [Abstract][Full Text] [Related]
13. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
[TBL] [Abstract][Full Text] [Related]
14. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
15. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
Wardrop D; Steensma DP
Br J Haematol; 2009 Mar; 144(6):809-17. PubMed ID: 19120370
[TBL] [Abstract][Full Text] [Related]
16. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK2 mutations in RARS and other MDS.
Hellström-Lindberg E; Cazzola M
Hematology Am Soc Hematol Educ Program; 2008; ():52-9. PubMed ID: 19074058
[TBL] [Abstract][Full Text] [Related]
18. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
19. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
[No Abstract] [Full Text] [Related]
20. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
